Trial
NCT00943553
A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction Chemotherapy Compared With Immediate Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Eisai Inc.
Collaborators
—
Condition
Acute Myelogenous Leukemia (AML)
Intervention
decitabine Induction Chemotherapy
Why stopped
Terminated by Sponsor
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-04-13